

Date of Deposit: January 8, 2008



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/665,079 Confirmation No. 6072  
Applicant : Nicholas G. **BACOPOULOS**, *et al.*  
Filed : September 16, 2003  
TC/A.U. : 1614  
Examiner : James D. **ANDERSON**  
Docket No. : 24852-501 CIP5  
Customer No. : 35437  
For : **METHODS OF TREATING CANCER WITH  
HDAC INHIBITORS**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, a copy of which is submitted herewith.

This Supplemental Information Disclosure Statement is being filed more than three months after the filing date of this application but before mailing of any Final Action or Notice of Allowance under 37 C.F.R. §§1.113 or 1.311, respectively. Accordingly, the fee of \$180 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is

considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Ref. No. **24852-501 CIP5**. Please address all correspondence to Customer Number **35437**.

Respectfully submitted,


Dated: January 8, 2008

*Michelle A. Iwamoto*

---

Ivor Elrifi, Reg. No. 39,529  
Michelle A. Iwamoto, Reg. No. 55,296  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*  
666 Third Avenue, 24<sup>th</sup> Floor  
New York, New York 10017  
Phone: (212) 935-3000  
Fax: (212) 983-3115

/ Please type a plus sign (+) in this box ☐



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/665,079
	Filing Date	September 16, 2003
	First Named Inventor	Bacopoulos
	Group Art Unit / Confirmation No.	1614 / 6072
	Examiner Name	James D. Anderson
	Attorney Docket Number	24852-501 CIP5

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No

NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C141	Ryan et al. (2003); "A Phase I Trial of an Oral Histone Deacetylase Inhibitor, MS-275, in Advanced Solid Tumor and Lymphoma Patients"; Proc. Am. Soc. Clin. Oncol. 22; 2003 ASCO Annual Meeting, Abstract No. 802.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.